There is pressure on drug companies to delay TV advertising of new drugs until doctors have had time to get up to speed. So this explains why PFE won't start publicity on Exubera until six months after launch. I'm still primarily into NOV calls on NKTR. There is the summer plus the election to get through, and small caps are weak in general. So NKTR could vegetate in this area.